The promise of human embryonic stem cell therapies

Robert Lanza, MD

VP Medical & Scientific Development

Advanced Cell Technology

and Adjunct Professor

Wake Forest University School of Medicine

CAUTIONARY STATEMENTCONCERNING FORWARD-LOOKING STATEMENTS

This presentation contains “forward-looking statements” as defined under the federal securities laws. Actual results could vary materially. Factors that could cause actual results to vary materially are described in our filings with the Securities and Exchange Commission. You should pay particular attention to the “risk factors” contained in documents we file from time to time with the Securities and Exchange Commission. The risks identified therein, as well as others not identified by the Company, could cause the Company’s actual results to differ materially from those expressed in any forward-looking statements.

0

10

20

30

40

50

60

70

1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998

Waiting ListOrgans Transplanted

•Parkinson’s ($6 billion/yr)•Stroke ($45 billion/yr)

•Spinal cord injury ($10 billion/yr)•Epilepsy ($3 billion/yr)

•Alzheimer’s ($100 billion/yr)•Multiple sclerosis ($10 billion/yr)

Production of new hES lines that will be safe for

clinical applications

• Feeder-free system• Serum-free system• Elimination of all

animal products, including sialic acids

• Generated using good manufacturing practice (GMP)

A B

C D

E

F

A B

C D

E

F

Generation of ES cells using parthenogenesis

WBC colony from cloned stem cells

•Cardiovascular disease costs the US $329 billion annually

End-stage renal disease will cost US $1 trillion during the coming decade